Randomized trial explores how alogliptin improves memory dysfunction in rats with diabetes, suggesting therapeutic potential.
Key Points
This research investigates the effects of alogliptin on cognitive impairments caused by diabetes in rats. It aims to understand the underlying mechanisms through which alogliptin mitigates neuroinflammation.
Induced Type 2 Diabetes Mellitus (T2DM) in rats using a high-fat diet followed by streptozotocin injection.
Administered alogliptin at dosages of 20 mg/kg/day and 40 mg/kg/day for 28 days.
Evaluated memory function using the Morris Water Maze and Y-maze tests, followed by biochemical and immunohistochemical analyses of brain tissue.
Alogliptin significantly improved memory function in the T2DM rats assessed by Morris Water Maze and Y-maze tests.
Reduced levels of neuroinflammatory markers HMGB1, RAGE, and TLR4/NF-κB signaling were observed, leading to decreased TNF-α and IL-1β cytokines.
Enhanced antioxidant activity was noted with increased SOD, CAT, and GSH levels and decreased MDA levels.